A Randomized, Double-Blind, Multicenter, Biphasic, Controlled With GARDASIL Dose-Escalation Study of Octavalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Adjuvanted With Amorphous Aluminum Hydroxyphosphate Sulfate (AAHS) and ISCOMATRIX (IMX).
Phase of Trial: Phase I
Latest Information Update: 09 Jan 2015
At a glance
- Drugs Aluminium hydroxyphosphate sulfate (Primary) ; Human papillomavirus vaccine recombinant octavalent Merck (Primary) ; Iscomatrix (Primary) ; Human papillomavirus vaccine recombinant quadrivalent Merck
- Indications Cervical cancer; Human papillomavirus infections
- Focus Pharmacodynamics
- 18 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Feb 2009 New trial record